X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
X4 Pharmaceuticals (Nasdaq: XFOR) issued inducement option awards effective March 31, 2026, granting options to purchase an aggregate of 32,000 shares under its 2019 Inducement Equity Incentive Plan.
The options carry a 10-year term, an exercise price of $4.13 (closing price on March 31, 2026) and a four-year vesting schedule (25% after 12 months, then monthly over 36 months).
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – XFOR
On the day this news was published, XFOR declined 2.53%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.4% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $11M from the company's valuation, bringing the market cap to $405.96M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
XFOR is up 3.51% while peer scanner shows ACET down about 2.47% and UNCY up about 1.98%, indicating mixed peer moves and a stock-specific reaction to news.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 17 | Earnings and update | Positive | +18.8% | Q4 and 2025 results plus 4WARD trial and cash runway update. |
| Mar 04 | Conference participation | Positive | +5.1% | Announcement of participation in Leerink Global Healthcare Conference. |
| Mar 02 | Inducement grants | Neutral | -2.1% | Inducement stock options for 24,000 shares to new employees. |
| Feb 27 | Regulatory opinion | Positive | +5.8% | Positive EMA CHMP opinion recommending EU approval for mavorixafor. |
| Feb 03 | Conference participation | Neutral | +0.5% | Participation in Guggenheim Emerging Outlook: Biotech Summit 2026. |
Recent XFOR news has generally coincided with positive price reactions, including earnings, CHMP opinion, and conference participation, while prior inducement grants saw a modest decline.
Over recent months, X4 Pharmaceuticals has reported key milestones, including Q4 and full‑year 2025 results with a cash position of $253.0M and progress on the Phase 3 4WARD trial. A positive CHMP opinion for mavorixafor in WHIM syndrome and participation in multiple conferences highlighted strategic progress. A February inducement grant under Nasdaq Listing Rule 5635(c)(4) involved options for 24,000 shares with a 10-year term. Today’s new inducement awards under the same framework continue that pattern of equity-based hiring incentives.
Regulatory & Risk Context
The company has an active Form S-3 shelf filed on 2025-09-10, used to register resale of shares held by selling stockholders. It has recorded 2 related 424B5 usages, and the shelf is noted as not effective in the provided context.
Market Pulse Summary
This announcement details new employee inducement stock options for 32,000 shares at a strike of $4.13 with a 10-year term and four-year vesting. It follows a previous inducement grant in February and comes after earnings highlighting $253.0M in cash and progress on the Phase 3 4WARD trial. Investors may watch future equity awards, financing activity under the Form S-3, and regulatory milestones for mavorixafor as key factors shaping the equity profile.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. Not financial advice.
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on March 31, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. The inducement awards consist of options to purchase an aggregate of 32,000 shares of X4’s common stock. These stock awards were granted as an inducement material to the new employees entering into employment with X4 in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by X4’s Compensation Committee of the Board of Directors.
The options have a ten-year term and an exercise price of
About X4 Pharmaceuticals
X4 Pharmaceuticals is a company focused on improving the lives of people with rare hematology diseases by developing and commercializing innovative therapies in areas with significant unmet needs. Leveraging expertise in diseases of the immune system and CXCR4 biology, X4 has successfully developed mavorixafor, an orally available CXCR4 antagonist that is commercially available in the U.S. as XOLREMDI® in its first indication. The Company is currently conducting a global, pivotal Phase 3 clinical trial (4WARD) evaluating mavorixafor in chronic neutropenic disorders. The U.S. FDA has granted Fast Track designation to mavorixafor for the treatment of chronic neutropenia. X4 is headquartered in Boston, Massachusetts. For more information, please visit www.x4pharma.com.
X4 Investor Contact:
Remy Bernarda
Jenny Kobin
IR Advisory Solutions
IR@X4pharma.com
Source: X4 Pharmaceuticals, Inc.
